Global Bio Simulation research
Global Bio Simulation research

Bio Simulation Comprehensive Study by Type (Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software, Toxicity Prediction Software, Other}, Services {In-house Services, Contract Services}), Application (Drug Development {Preclinical Testing, Clinical Trials}, Drug Discovery{ Target Identification and Validation, Lead Identification and Optimization}, Other), End Users (Pharmaceutical & Biotechnology Companies, Research Institutes, Contract Research Organizations, Regulatory Authorities, Other), Delivery Model (Subscription Models, Ownership Models) Players and Region - Global Market Outlook to 2026

Bio Simulation Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026 | CAGR: 16.02%  

Jan 2021 Edition 208 Pages 165 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Bio Simulation Market Overview:
Bio simulation denotes simulation of the dynamics of biological systems. It analyzes and predicts system behavior in terms of mathematical expression with the help of modern computers. Bio simulation is a relatively new tool in pharmaceutical drug development & healthcare that has tremendous benefits and improves the predictability in the early stages of drug development. Bio simulation uses a mathematical representation of the real-life processes inside the human body that are expressed in interconnected sets of differential equations. The various technological advancements and increasing occurrences of various chronic diseases will contribute the market growth in the coming years. Some of the players profiled in the study are Certara (United States), Simulations Plus (United States), Dassault Systèmes (France), Schrödinger (United States), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (United Kingdom), Evidera (United States), In silico biosciences (United States), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (United States), Nuventra Pharma (United States) and Genedata (Switzerland). According to Market Analyst at AMA, the Global Bio Simulation market may see a growth rate of 16.02%

On the basis of geography, the market of Bio Simulation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Pharmaceutical & Biotechnology Companies will boost the Bio Simulation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Delivery Model, the sub-segment i.e. Subscription Models will boost the Bio Simulation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Growth Of Pharmaceutical And Biotech Industries
  • Increasing Adoption Of Bio Simulation Software By Regulatory Bodies
  • Rising Growth Of Biologics And Biosimilars Markets

Influencing Trend
  • Technological Advancement QSP Systems

Restraints
  • Lack Of Standardization

Opportunities
  • Government Investments In R&D
  • Need to Decrease Drug Discovery and Development Costs
  • Demand For Personalized Medicines

Challenges
  • Shortage Of Bio Simulation And Modeling Experts


Key Market Developments:


In June 2020, Certara launched updation of its Phoenix platform, a bio simulation software for drug development. The Phoenix platform version 8.3 updation includes Phoenix NLME, Phoenix Built-In Plots, and Open Source Plotting.

The intense competition, changing consumer spending patterns, demographic trends, and increasing investments by key players pose significant growth opportunities for the global bio simulation market in forecast years.

Target Audience:
New Entrants/Investors, Analysts and Strategic Business Planners, Bio Simulation Providers, Software Providers, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Bio Simulation market on the basis of product [Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software, Toxicity Prediction Software, Other} and Services {In-house Services, Contract Services}] , application [Drug Development {Preclinical Testing, Clinical Trials}, Drug Discovery{ Target Identification and Validation, Lead Identification and Optimization} and Other], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Bio Simulation market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Bio Simulation industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Bio Simulation market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software, Toxicity Prediction Software, Other}
  • Services {In-house Services, Contract Services}
By Application
  • Drug Development {Preclinical Testing, Clinical Trials}
  • Drug Discovery{ Target Identification and Validation, Lead Identification and Optimization}
  • Other
By End Users
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Contract Research Organizations
  • Regulatory Authorities
  • Other

By Delivery Model
  • Subscription Models
  • Ownership Models

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth Of Pharmaceutical And Biotech Industries
      • 3.2.2. Increasing Adoption Of Bio Simulation Software By Regulatory Bodies
      • 3.2.3. Rising Growth Of Biologics And Biosimilars Markets
    • 3.3. Market Challenges
      • 3.3.1. Shortage Of Bio Simulation And Modeling Experts
    • 3.4. Market Trends
      • 3.4.1. Technological Advancement QSP Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bio Simulation, by Type, Application, End Users, Delivery Model and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Bio Simulation (Value)
      • 5.2.1. Global Bio Simulation by: Type (Value)
        • 5.2.1.1. Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software, Toxicity Prediction Software, Other}
        • 5.2.1.2. Services {In-house Services, Contract Services}
      • 5.2.2. Global Bio Simulation by: Application (Value)
        • 5.2.2.1. Drug Development {Preclinical Testing, Clinical Trials}
        • 5.2.2.2. Drug Discovery{ Target Identification and Validation, Lead Identification and Optimization}
        • 5.2.2.3. Other
      • 5.2.3. Global Bio Simulation by: End Users (Value)
        • 5.2.3.1. Pharmaceutical & Biotechnology Companies
        • 5.2.3.2. Research Institutes
        • 5.2.3.3. Contract Research Organizations
        • 5.2.3.4. Regulatory Authorities
        • 5.2.3.5. Other
      • 5.2.4. Global Bio Simulation by: Delivery Model (Value)
        • 5.2.4.1. Subscription Models
        • 5.2.4.2. Ownership Models
      • 5.2.5. Global Bio Simulation Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Bio Simulation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Certara (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Simulations Plus (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dassault Systèmes (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Schrödinger (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ACD/Labs (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Chemical Computing Group (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Physiomics (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Evidera (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. In silico biosciences (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. INOSIM Software (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Insilico Biotechnology (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. LeadInvent Technologies (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Rosa (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Nuventra Pharma (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Genedata (Switzerland)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Bio Simulation Sale, by Type, Application, End Users, Delivery Model and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Bio Simulation (Value)
      • 7.2.1. Global Bio Simulation by: Type (Value)
        • 7.2.1.1. Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software, Toxicity Prediction Software, Other}
        • 7.2.1.2. Services {In-house Services, Contract Services}
      • 7.2.2. Global Bio Simulation by: Application (Value)
        • 7.2.2.1. Drug Development {Preclinical Testing, Clinical Trials}
        • 7.2.2.2. Drug Discovery{ Target Identification and Validation, Lead Identification and Optimization}
        • 7.2.2.3. Other
      • 7.2.3. Global Bio Simulation by: End Users (Value)
        • 7.2.3.1. Pharmaceutical & Biotechnology Companies
        • 7.2.3.2. Research Institutes
        • 7.2.3.3. Contract Research Organizations
        • 7.2.3.4. Regulatory Authorities
        • 7.2.3.5. Other
      • 7.2.4. Global Bio Simulation by: Delivery Model (Value)
        • 7.2.4.1. Subscription Models
        • 7.2.4.2. Ownership Models
      • 7.2.5. Global Bio Simulation Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bio Simulation: by Type(USD Million)
  • Table 2. Bio Simulation Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software, Toxicity Prediction Software, Other} , by Region USD Million (2015-2020)
  • Table 3. Bio Simulation Services {In-house Services, Contract Services} , by Region USD Million (2015-2020)
  • Table 4. Bio Simulation: by Application(USD Million)
  • Table 5. Bio Simulation Drug Development {Preclinical Testing, Clinical Trials} , by Region USD Million (2015-2020)
  • Table 6. Bio Simulation Drug Discovery{ Target Identification and Validation, Lead Identification and Optimization} , by Region USD Million (2015-2020)
  • Table 7. Bio Simulation Other , by Region USD Million (2015-2020)
  • Table 8. Bio Simulation: by End Users(USD Million)
  • Table 9. Bio Simulation Pharmaceutical & Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 10. Bio Simulation Research Institutes , by Region USD Million (2015-2020)
  • Table 11. Bio Simulation Contract Research Organizations , by Region USD Million (2015-2020)
  • Table 12. Bio Simulation Regulatory Authorities , by Region USD Million (2015-2020)
  • Table 13. Bio Simulation Other , by Region USD Million (2015-2020)
  • Table 14. Bio Simulation: by Delivery Model(USD Million)
  • Table 15. Bio Simulation Subscription Models , by Region USD Million (2015-2020)
  • Table 16. Bio Simulation Ownership Models , by Region USD Million (2015-2020)
  • Table 17. South America Bio Simulation, by Country USD Million (2015-2020)
  • Table 18. South America Bio Simulation, by Type USD Million (2015-2020)
  • Table 19. South America Bio Simulation, by Application USD Million (2015-2020)
  • Table 20. South America Bio Simulation, by End Users USD Million (2015-2020)
  • Table 21. South America Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 22. Brazil Bio Simulation, by Type USD Million (2015-2020)
  • Table 23. Brazil Bio Simulation, by Application USD Million (2015-2020)
  • Table 24. Brazil Bio Simulation, by End Users USD Million (2015-2020)
  • Table 25. Brazil Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 26. Argentina Bio Simulation, by Type USD Million (2015-2020)
  • Table 27. Argentina Bio Simulation, by Application USD Million (2015-2020)
  • Table 28. Argentina Bio Simulation, by End Users USD Million (2015-2020)
  • Table 29. Argentina Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 30. Rest of South America Bio Simulation, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Bio Simulation, by Application USD Million (2015-2020)
  • Table 32. Rest of South America Bio Simulation, by End Users USD Million (2015-2020)
  • Table 33. Rest of South America Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 34. Asia Pacific Bio Simulation, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Bio Simulation, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Bio Simulation, by Application USD Million (2015-2020)
  • Table 37. Asia Pacific Bio Simulation, by End Users USD Million (2015-2020)
  • Table 38. Asia Pacific Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 39. China Bio Simulation, by Type USD Million (2015-2020)
  • Table 40. China Bio Simulation, by Application USD Million (2015-2020)
  • Table 41. China Bio Simulation, by End Users USD Million (2015-2020)
  • Table 42. China Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 43. Japan Bio Simulation, by Type USD Million (2015-2020)
  • Table 44. Japan Bio Simulation, by Application USD Million (2015-2020)
  • Table 45. Japan Bio Simulation, by End Users USD Million (2015-2020)
  • Table 46. Japan Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 47. India Bio Simulation, by Type USD Million (2015-2020)
  • Table 48. India Bio Simulation, by Application USD Million (2015-2020)
  • Table 49. India Bio Simulation, by End Users USD Million (2015-2020)
  • Table 50. India Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 51. South Korea Bio Simulation, by Type USD Million (2015-2020)
  • Table 52. South Korea Bio Simulation, by Application USD Million (2015-2020)
  • Table 53. South Korea Bio Simulation, by End Users USD Million (2015-2020)
  • Table 54. South Korea Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 55. Taiwan Bio Simulation, by Type USD Million (2015-2020)
  • Table 56. Taiwan Bio Simulation, by Application USD Million (2015-2020)
  • Table 57. Taiwan Bio Simulation, by End Users USD Million (2015-2020)
  • Table 58. Taiwan Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 59. Australia Bio Simulation, by Type USD Million (2015-2020)
  • Table 60. Australia Bio Simulation, by Application USD Million (2015-2020)
  • Table 61. Australia Bio Simulation, by End Users USD Million (2015-2020)
  • Table 62. Australia Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Bio Simulation, by Type USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Bio Simulation, by Application USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Bio Simulation, by End Users USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 67. Europe Bio Simulation, by Country USD Million (2015-2020)
  • Table 68. Europe Bio Simulation, by Type USD Million (2015-2020)
  • Table 69. Europe Bio Simulation, by Application USD Million (2015-2020)
  • Table 70. Europe Bio Simulation, by End Users USD Million (2015-2020)
  • Table 71. Europe Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 72. Germany Bio Simulation, by Type USD Million (2015-2020)
  • Table 73. Germany Bio Simulation, by Application USD Million (2015-2020)
  • Table 74. Germany Bio Simulation, by End Users USD Million (2015-2020)
  • Table 75. Germany Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 76. France Bio Simulation, by Type USD Million (2015-2020)
  • Table 77. France Bio Simulation, by Application USD Million (2015-2020)
  • Table 78. France Bio Simulation, by End Users USD Million (2015-2020)
  • Table 79. France Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 80. Italy Bio Simulation, by Type USD Million (2015-2020)
  • Table 81. Italy Bio Simulation, by Application USD Million (2015-2020)
  • Table 82. Italy Bio Simulation, by End Users USD Million (2015-2020)
  • Table 83. Italy Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 84. United Kingdom Bio Simulation, by Type USD Million (2015-2020)
  • Table 85. United Kingdom Bio Simulation, by Application USD Million (2015-2020)
  • Table 86. United Kingdom Bio Simulation, by End Users USD Million (2015-2020)
  • Table 87. United Kingdom Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 88. Netherlands Bio Simulation, by Type USD Million (2015-2020)
  • Table 89. Netherlands Bio Simulation, by Application USD Million (2015-2020)
  • Table 90. Netherlands Bio Simulation, by End Users USD Million (2015-2020)
  • Table 91. Netherlands Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 92. Rest of Europe Bio Simulation, by Type USD Million (2015-2020)
  • Table 93. Rest of Europe Bio Simulation, by Application USD Million (2015-2020)
  • Table 94. Rest of Europe Bio Simulation, by End Users USD Million (2015-2020)
  • Table 95. Rest of Europe Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 96. MEA Bio Simulation, by Country USD Million (2015-2020)
  • Table 97. MEA Bio Simulation, by Type USD Million (2015-2020)
  • Table 98. MEA Bio Simulation, by Application USD Million (2015-2020)
  • Table 99. MEA Bio Simulation, by End Users USD Million (2015-2020)
  • Table 100. MEA Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 101. Middle East Bio Simulation, by Type USD Million (2015-2020)
  • Table 102. Middle East Bio Simulation, by Application USD Million (2015-2020)
  • Table 103. Middle East Bio Simulation, by End Users USD Million (2015-2020)
  • Table 104. Middle East Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 105. Africa Bio Simulation, by Type USD Million (2015-2020)
  • Table 106. Africa Bio Simulation, by Application USD Million (2015-2020)
  • Table 107. Africa Bio Simulation, by End Users USD Million (2015-2020)
  • Table 108. Africa Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 109. North America Bio Simulation, by Country USD Million (2015-2020)
  • Table 110. North America Bio Simulation, by Type USD Million (2015-2020)
  • Table 111. North America Bio Simulation, by Application USD Million (2015-2020)
  • Table 112. North America Bio Simulation, by End Users USD Million (2015-2020)
  • Table 113. North America Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 114. United States Bio Simulation, by Type USD Million (2015-2020)
  • Table 115. United States Bio Simulation, by Application USD Million (2015-2020)
  • Table 116. United States Bio Simulation, by End Users USD Million (2015-2020)
  • Table 117. United States Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 118. Canada Bio Simulation, by Type USD Million (2015-2020)
  • Table 119. Canada Bio Simulation, by Application USD Million (2015-2020)
  • Table 120. Canada Bio Simulation, by End Users USD Million (2015-2020)
  • Table 121. Canada Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 122. Mexico Bio Simulation, by Type USD Million (2015-2020)
  • Table 123. Mexico Bio Simulation, by Application USD Million (2015-2020)
  • Table 124. Mexico Bio Simulation, by End Users USD Million (2015-2020)
  • Table 125. Mexico Bio Simulation, by Delivery Model USD Million (2015-2020)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Bio Simulation: by Type(USD Million)
  • Table 142. Bio Simulation Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software, Toxicity Prediction Software, Other} , by Region USD Million (2021-2026)
  • Table 143. Bio Simulation Services {In-house Services, Contract Services} , by Region USD Million (2021-2026)
  • Table 144. Bio Simulation: by Application(USD Million)
  • Table 145. Bio Simulation Drug Development {Preclinical Testing, Clinical Trials} , by Region USD Million (2021-2026)
  • Table 146. Bio Simulation Drug Discovery{ Target Identification and Validation, Lead Identification and Optimization} , by Region USD Million (2021-2026)
  • Table 147. Bio Simulation Other , by Region USD Million (2021-2026)
  • Table 148. Bio Simulation: by End Users(USD Million)
  • Table 149. Bio Simulation Pharmaceutical & Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 150. Bio Simulation Research Institutes , by Region USD Million (2021-2026)
  • Table 151. Bio Simulation Contract Research Organizations , by Region USD Million (2021-2026)
  • Table 152. Bio Simulation Regulatory Authorities , by Region USD Million (2021-2026)
  • Table 153. Bio Simulation Other , by Region USD Million (2021-2026)
  • Table 154. Bio Simulation: by Delivery Model(USD Million)
  • Table 155. Bio Simulation Subscription Models , by Region USD Million (2021-2026)
  • Table 156. Bio Simulation Ownership Models , by Region USD Million (2021-2026)
  • Table 157. South America Bio Simulation, by Country USD Million (2021-2026)
  • Table 158. South America Bio Simulation, by Type USD Million (2021-2026)
  • Table 159. South America Bio Simulation, by Application USD Million (2021-2026)
  • Table 160. South America Bio Simulation, by End Users USD Million (2021-2026)
  • Table 161. South America Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 162. Brazil Bio Simulation, by Type USD Million (2021-2026)
  • Table 163. Brazil Bio Simulation, by Application USD Million (2021-2026)
  • Table 164. Brazil Bio Simulation, by End Users USD Million (2021-2026)
  • Table 165. Brazil Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 166. Argentina Bio Simulation, by Type USD Million (2021-2026)
  • Table 167. Argentina Bio Simulation, by Application USD Million (2021-2026)
  • Table 168. Argentina Bio Simulation, by End Users USD Million (2021-2026)
  • Table 169. Argentina Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 170. Rest of South America Bio Simulation, by Type USD Million (2021-2026)
  • Table 171. Rest of South America Bio Simulation, by Application USD Million (2021-2026)
  • Table 172. Rest of South America Bio Simulation, by End Users USD Million (2021-2026)
  • Table 173. Rest of South America Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 174. Asia Pacific Bio Simulation, by Country USD Million (2021-2026)
  • Table 175. Asia Pacific Bio Simulation, by Type USD Million (2021-2026)
  • Table 176. Asia Pacific Bio Simulation, by Application USD Million (2021-2026)
  • Table 177. Asia Pacific Bio Simulation, by End Users USD Million (2021-2026)
  • Table 178. Asia Pacific Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 179. China Bio Simulation, by Type USD Million (2021-2026)
  • Table 180. China Bio Simulation, by Application USD Million (2021-2026)
  • Table 181. China Bio Simulation, by End Users USD Million (2021-2026)
  • Table 182. China Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 183. Japan Bio Simulation, by Type USD Million (2021-2026)
  • Table 184. Japan Bio Simulation, by Application USD Million (2021-2026)
  • Table 185. Japan Bio Simulation, by End Users USD Million (2021-2026)
  • Table 186. Japan Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 187. India Bio Simulation, by Type USD Million (2021-2026)
  • Table 188. India Bio Simulation, by Application USD Million (2021-2026)
  • Table 189. India Bio Simulation, by End Users USD Million (2021-2026)
  • Table 190. India Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 191. South Korea Bio Simulation, by Type USD Million (2021-2026)
  • Table 192. South Korea Bio Simulation, by Application USD Million (2021-2026)
  • Table 193. South Korea Bio Simulation, by End Users USD Million (2021-2026)
  • Table 194. South Korea Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 195. Taiwan Bio Simulation, by Type USD Million (2021-2026)
  • Table 196. Taiwan Bio Simulation, by Application USD Million (2021-2026)
  • Table 197. Taiwan Bio Simulation, by End Users USD Million (2021-2026)
  • Table 198. Taiwan Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 199. Australia Bio Simulation, by Type USD Million (2021-2026)
  • Table 200. Australia Bio Simulation, by Application USD Million (2021-2026)
  • Table 201. Australia Bio Simulation, by End Users USD Million (2021-2026)
  • Table 202. Australia Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Bio Simulation, by Type USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Bio Simulation, by Application USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Bio Simulation, by End Users USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 207. Europe Bio Simulation, by Country USD Million (2021-2026)
  • Table 208. Europe Bio Simulation, by Type USD Million (2021-2026)
  • Table 209. Europe Bio Simulation, by Application USD Million (2021-2026)
  • Table 210. Europe Bio Simulation, by End Users USD Million (2021-2026)
  • Table 211. Europe Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 212. Germany Bio Simulation, by Type USD Million (2021-2026)
  • Table 213. Germany Bio Simulation, by Application USD Million (2021-2026)
  • Table 214. Germany Bio Simulation, by End Users USD Million (2021-2026)
  • Table 215. Germany Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 216. France Bio Simulation, by Type USD Million (2021-2026)
  • Table 217. France Bio Simulation, by Application USD Million (2021-2026)
  • Table 218. France Bio Simulation, by End Users USD Million (2021-2026)
  • Table 219. France Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 220. Italy Bio Simulation, by Type USD Million (2021-2026)
  • Table 221. Italy Bio Simulation, by Application USD Million (2021-2026)
  • Table 222. Italy Bio Simulation, by End Users USD Million (2021-2026)
  • Table 223. Italy Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 224. United Kingdom Bio Simulation, by Type USD Million (2021-2026)
  • Table 225. United Kingdom Bio Simulation, by Application USD Million (2021-2026)
  • Table 226. United Kingdom Bio Simulation, by End Users USD Million (2021-2026)
  • Table 227. United Kingdom Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 228. Netherlands Bio Simulation, by Type USD Million (2021-2026)
  • Table 229. Netherlands Bio Simulation, by Application USD Million (2021-2026)
  • Table 230. Netherlands Bio Simulation, by End Users USD Million (2021-2026)
  • Table 231. Netherlands Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 232. Rest of Europe Bio Simulation, by Type USD Million (2021-2026)
  • Table 233. Rest of Europe Bio Simulation, by Application USD Million (2021-2026)
  • Table 234. Rest of Europe Bio Simulation, by End Users USD Million (2021-2026)
  • Table 235. Rest of Europe Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 236. MEA Bio Simulation, by Country USD Million (2021-2026)
  • Table 237. MEA Bio Simulation, by Type USD Million (2021-2026)
  • Table 238. MEA Bio Simulation, by Application USD Million (2021-2026)
  • Table 239. MEA Bio Simulation, by End Users USD Million (2021-2026)
  • Table 240. MEA Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 241. Middle East Bio Simulation, by Type USD Million (2021-2026)
  • Table 242. Middle East Bio Simulation, by Application USD Million (2021-2026)
  • Table 243. Middle East Bio Simulation, by End Users USD Million (2021-2026)
  • Table 244. Middle East Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 245. Africa Bio Simulation, by Type USD Million (2021-2026)
  • Table 246. Africa Bio Simulation, by Application USD Million (2021-2026)
  • Table 247. Africa Bio Simulation, by End Users USD Million (2021-2026)
  • Table 248. Africa Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 249. North America Bio Simulation, by Country USD Million (2021-2026)
  • Table 250. North America Bio Simulation, by Type USD Million (2021-2026)
  • Table 251. North America Bio Simulation, by Application USD Million (2021-2026)
  • Table 252. North America Bio Simulation, by End Users USD Million (2021-2026)
  • Table 253. North America Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 254. United States Bio Simulation, by Type USD Million (2021-2026)
  • Table 255. United States Bio Simulation, by Application USD Million (2021-2026)
  • Table 256. United States Bio Simulation, by End Users USD Million (2021-2026)
  • Table 257. United States Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 258. Canada Bio Simulation, by Type USD Million (2021-2026)
  • Table 259. Canada Bio Simulation, by Application USD Million (2021-2026)
  • Table 260. Canada Bio Simulation, by End Users USD Million (2021-2026)
  • Table 261. Canada Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 262. Mexico Bio Simulation, by Type USD Million (2021-2026)
  • Table 263. Mexico Bio Simulation, by Application USD Million (2021-2026)
  • Table 264. Mexico Bio Simulation, by End Users USD Million (2021-2026)
  • Table 265. Mexico Bio Simulation, by Delivery Model USD Million (2021-2026)
  • Table 266. Research Programs/Design for This Report
  • Table 267. Key Data Information from Secondary Sources
  • Table 268. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bio Simulation: by Type USD Million (2015-2020)
  • Figure 5. Global Bio Simulation: by Application USD Million (2015-2020)
  • Figure 6. Global Bio Simulation: by End Users USD Million (2015-2020)
  • Figure 7. Global Bio Simulation: by Delivery Model USD Million (2015-2020)
  • Figure 8. South America Bio Simulation Share (%), by Country
  • Figure 9. Asia Pacific Bio Simulation Share (%), by Country
  • Figure 10. Europe Bio Simulation Share (%), by Country
  • Figure 11. MEA Bio Simulation Share (%), by Country
  • Figure 12. North America Bio Simulation Share (%), by Country
  • Figure 13. Global Bio Simulation share by Players 2020 (%)
  • Figure 14. Global Bio Simulation share by Players (Top 3) 2020(%)
  • Figure 15. Global Bio Simulation share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Certara (United States) Revenue, Net Income and Gross profit
  • Figure 18. Certara (United States) Revenue: by Geography 2020
  • Figure 19. Simulations Plus (United States) Revenue, Net Income and Gross profit
  • Figure 20. Simulations Plus (United States) Revenue: by Geography 2020
  • Figure 21. Dassault Systèmes (France) Revenue, Net Income and Gross profit
  • Figure 22. Dassault Systèmes (France) Revenue: by Geography 2020
  • Figure 23. Schrödinger (United States) Revenue, Net Income and Gross profit
  • Figure 24. Schrödinger (United States) Revenue: by Geography 2020
  • Figure 25. ACD/Labs (Canada) Revenue, Net Income and Gross profit
  • Figure 26. ACD/Labs (Canada) Revenue: by Geography 2020
  • Figure 27. Chemical Computing Group (Canada) Revenue, Net Income and Gross profit
  • Figure 28. Chemical Computing Group (Canada) Revenue: by Geography 2020
  • Figure 29. Physiomics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Physiomics (United Kingdom) Revenue: by Geography 2020
  • Figure 31. Evidera (United States) Revenue, Net Income and Gross profit
  • Figure 32. Evidera (United States) Revenue: by Geography 2020
  • Figure 33. In silico biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 34. In silico biosciences (United States) Revenue: by Geography 2020
  • Figure 35. INOSIM Software (Germany) Revenue, Net Income and Gross profit
  • Figure 36. INOSIM Software (Germany) Revenue: by Geography 2020
  • Figure 37. Insilico Biotechnology (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Insilico Biotechnology (Germany) Revenue: by Geography 2020
  • Figure 39. LeadInvent Technologies (India) Revenue, Net Income and Gross profit
  • Figure 40. LeadInvent Technologies (India) Revenue: by Geography 2020
  • Figure 41. Rosa (United States) Revenue, Net Income and Gross profit
  • Figure 42. Rosa (United States) Revenue: by Geography 2020
  • Figure 43. Nuventra Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 44. Nuventra Pharma (United States) Revenue: by Geography 2020
  • Figure 45. Genedata (Switzerland) Revenue, Net Income and Gross profit
  • Figure 46. Genedata (Switzerland) Revenue: by Geography 2020
  • Figure 47. Global Bio Simulation: by Type USD Million (2021-2026)
  • Figure 48. Global Bio Simulation: by Application USD Million (2021-2026)
  • Figure 49. Global Bio Simulation: by End Users USD Million (2021-2026)
  • Figure 50. Global Bio Simulation: by Delivery Model USD Million (2021-2026)
  • Figure 51. South America Bio Simulation Share (%), by Country
  • Figure 52. Asia Pacific Bio Simulation Share (%), by Country
  • Figure 53. Europe Bio Simulation Share (%), by Country
  • Figure 54. MEA Bio Simulation Share (%), by Country
  • Figure 55. North America Bio Simulation Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Certara (United States)
  • Simulations Plus (United States)
  • Dassault Systèmes (France)
  • Schrödinger (United States)
  • ACD/Labs (Canada)
  • Chemical Computing Group (Canada)
  • Physiomics (United Kingdom)
  • Evidera (United States)
  • In silico biosciences (United States)
  • INOSIM Software (Germany)
  • Insilico Biotechnology (Germany)
  • LeadInvent Technologies (India)
  • Rosa (United States)
  • Nuventra Pharma (United States)
  • Genedata (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation